Gao Yan, Pan Chang-Yu, Zou Da-Jin, Xu Zhang-Rong, Liu Xiao-Min, Guo Xiao-Hui
Department of Endocrinology, Peking University First Hospital, Beijing 100034, China.
Zhonghua Yi Xue Za Zhi. 2009 Jul 28;89(28):1960-3.
To compare the efficacy and safety of insulin aspart (IAsp) and human insulin (HI) when applied as meal-time insulin with neutral protamine Hagedorn insulin (NPH) at bedtime in diabetics.
A total of 220 Chinese subjects with type 1 or type 2 diabetes from 5 different hospitals were randomized by a ratio of 1:1 into two groups accepting IAsp or HI combined with NPH respectively. The main endpoints were assessed by fasting plasma glucose (FPG), 2 hour postprandial plasma glucose (2 h PPG), HbAlc and hypoglycemia.
A greater reduction in mean 2 h PPG was achieved in the IAsp group [(14.6 +/- 5.3) mmol/L] as compared with the HI group [(8.4 +/- 4.1) mmol/L] (P < 0.01, adjusted for baseline value, center effect and diabetes type). Significantly more IAsp-treated subjects reached the 2 h PPG target (50.0% vs 25.5%, P < 0.01). HbA1c was reduced more in IAsp/NPH group [(9.3 +/- 1.4)% vs (7.7 +/- 1.3)%] than in HI/NPH group [(9.2 +/- 1.2)% vs (7.7 +/- 1.2)%]. HbA1c target was reached by 24.5% (IAsp) vs 14.5% (HI) of subjects (P < 0.05). No major hypoglycemia or serious adverse events were observed for the IAsp group. Lower incidence of nocturnal hypoglycemia (IAsp/NPH: 3% vs HI/NPH: 4%) was reported in the IAsp group. Average daily insulin doses were 0.60/0.23 (IAsp/NPH) and 0.65/0.24 (HI/NPH) IU/kg respectively.
Treatment of IAsp in basal-bolus therapy in combination with NPH provides a superior postprandial glucose control and allows more subjects to reach the glycemic target without elevating the nocturnal hypoglycemic risk or adverse events.
比较门冬胰岛素(IAsp)与普通胰岛素(HI)作为餐时胰岛素联合中效低精蛋白锌胰岛素(NPH)睡前注射治疗糖尿病患者的疗效及安全性。
来自5家不同医院的220例1型或2型糖尿病中国患者按1:1比例随机分为两组,分别接受IAsp或HI联合NPH治疗。主要终点指标通过空腹血糖(FPG)、餐后2小时血糖(2 h PPG)、糖化血红蛋白(HbAlc)及低血糖情况进行评估。
与HI组[(8.4±4.1)mmol/L]相比,IAsp组[(14.6±5.3)mmol/L]餐后2小时平均血糖下降幅度更大(P<0.01,校正基线值、中心效应及糖尿病类型后)。达到餐后2小时血糖目标的IAsp治疗患者明显更多(50.0%对25.5%,P<0.01)。IAsp/NPH组HbA1c降低幅度大于HI/NPH组[(9.3±1.4)%对(7.7±1.3)%,(9.2±1.2)%对(7.7±1.2)%]。达到HbA1c目标的患者比例为24.5%(IAsp)对14.5%(HI)(P<0.05)。IAsp组未观察到严重低血糖或严重不良事件。IAsp组夜间低血糖发生率较低(IAsp/NPH:3%对HI/NPH:4%)。平均每日胰岛素剂量分别为0.60/0.23(IAsp/NPH)和0.65/0.24(HI/NPH)IU/kg。
IAsp在基础-餐时胰岛素治疗中联合NPH可提供更好的餐后血糖控制,使更多患者达到血糖目标,且不增加夜间低血糖风险或不良事件。